Cellbricks Therapeutics
3D bioprinting for replicating human tissue
- 21-100 employees
- Healthcare
- B2B
- Biology
- Science
- Wedding, Berlin, Germany
Jump to section
Company mission
To replicate human tissue at scale so that researchers and doctors can provide patients with better clinical treatments.
Our take
Cellbricks Therapeutics is at the forefront of addressing a critical challenge in modern medicine: the scarcity of donor organs and tissues for transplantation. With the global demand for organ transplants continually on the rise, the company stands as a biotech leader that combines world-leading expertise in synthetic biology and 3D printing.
Leveraging proprietary biofabrication technology and tissue engineering proficiency, the company facilitates the scalable replication of human tissue. This breakthrough has immense potential to transform clinical treatments, enabling researchers and doctors to provide patients with more effective and accessible solutions.
Cellbricks Therapeutics is working towards a future where the biofabrication of organs and human tissue becomes standard medical practice. This vision aligns with the broader goal of helping humanity enjoy longer, healthier lives, and makes the company one to watch as it invests fresh funding into accelerating preclinical validation for its technology.
Freddie
Company Specialist at Welcome to the Jungle
Benefits
- A high-growth, ambitious biotech startup environment
- Diverse team of talented & motivated individuals looking to make a difference
- Full ownership over exciting, challenging projects and full support to expand skills & boost personal development
- Flexibility, weekly team activities & regular events
Funding (1 round)
Mar 2026
$8.1m
SEED
Total funding: $8.1m
Leadership
Alexander Leutner
(CEO)Founded and was Managing Director at Apodius for 8.5 years, remaining as MD for another 4.5 years after its acquisition by Hexagon Manufacturing Intelligence.